Nasdaq · Biotech stocks database
LEGN (Legend Biotech Corporation) stock: $17.61, $3.42B market cap, $901.9M cash, $2.84B EV, $3.29B fully diluted market cap. Next expected readout: Dec-27. Lead program: LB1908 (Gastric Cancer), Phase 1. Data from Fully Diluted's biotech stocks database.
| Cash | $901.9M |
|---|---|
| Debt | $319.1M |
| Net cash | $582.8M |
| Enterprise value | $2,842.1M |
| Basic shares | 194.5M shares |
| Fully diluted shares | 186.7M shares |
| Fully diluted market cap | $3,288.5M |
| Cash per share | $4.64 |
Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Loading LEGN daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Jan 12 - Feb 23 | LB1908 | Phase 1 | Gastric Cancer; Gastroesophageal-junction Cancer; Esophageal Cancer | — |
| Jan 12 - Feb 23 | LB2102 | Phase 1 | Small Cell Lung Cancer Extensive Stage; Large Cell Neuroendocrine Carcinoma of the Lung | — |
| Mar 13 - Apr 24 | LUCAR-G79D T cells | Phase 1 | Systemic Lupus Erythematosus (SLE); Idiopathic Inflammatory Myopathies(IIM) | — |
| Feb 11 - Mar 25 | LUCAR-DKS1 NK cells | Early Phase 1 | Relapsed/Refractory Autoimmune Diseases | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.